Genetic Signatures (ASX:GSS) Other Gross PPE : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Genetic Signatures Other Gross PPE?

Genetic Signatures's Other Gross PPE for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Genetic Signatures's annual Other Gross PPE declined from Jun. 2021 (A$0.39 Mil) to Jun. 2022 (A$0.04 Mil) and declined from Jun. 2022 (A$0.04 Mil) to Jun. 2023 (A$0.00 Mil).

Genetic Signatures Other Gross PPE Historical Data

The historical data trend for Genetic Signatures's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Signatures Other Gross PPE Chart

Genetic Signatures Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Other Gross PPE

Get a 7-Day Free Trial

0.73

0.39

0.04

Genetic Signatures Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Gross PPE	Get a 7-Day Free Trial													-	0.04	-	-	-

Genetic Signatures Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Genetic Signatures (ASX:GSS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Signatures Ltd (ASX:GSS) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

N/A

Address

7 Eliza Street, Newtown, Sydney, NSW, AUS, 2042

Website

https://www.geneticsignatures.com

Genetic Signatures Ltd proprietary PCR solutions and automated workflows routinely screen for multiple infectious diseases in a single test. Rapid and accurate results facilitate improved patient management and healthcare outcomes. GSS continues to expand its global reach with direct representation in Australia, Europe, and the United States, and growing distribution partnerships. The company operates under one business segment which is the research and commercialisation of identifying individual genetic signatures to diagnose diseases and disabilities.